oldandintheway
yes, I think the q&a during next week's cc will press the CEO to address the confusion and disappointment concerning his decision to avoid letting shareholders know about the changes to the methods being used to present data.
Will he underscore the CRO's lack of updating? Will he accept responsibility for it?
Also, what's the path that the FDA wants him to follow at this point?
Timeline updates would be nice albeit he never is correct on that!
Any progress in Australia, Europe, elsewhere?
News 
Market Data 
Discover 
